JW (Cayman) Therapeutics Co. Company Description

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China.

It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer.

Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.

The company’s pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma.

JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.

JW (Cayman) Therapeutics Co. Ltd

Country	Cayman Islands
Founded	2016
Industry	Biotechnology
Sector	Healthcare
Employees	281
CEO	Min Liu

Contact Details

Address: Building B Shanghai China
Website	jwtherapeutics.com

Stock Details

Ticker Symbol	2126
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	KYG5210T1040
SIC Code	2836

Key Executives

Name	Position
Min Liu	Chief Executive Officer and Executive Chairman
Dr. Yiping Li M.D.	Co-Founder and Director
Cao Xiaoping Ph.D.	Senior Vice President of Tech Operations
Dr. Shaun Paul Cordoba Ph.D.	Senior Vice President and Chief Scientific Officer
Raymond J. Hage Jr.	Senior Vice President of Corporate Development
Mark J. Gilbert M.D.	Senior Advisor and Acting Chief Medical Officer
Qiang Ma	Senior Vice President and Chief Commercial Officer
Yun Qin	Senior Vice President of Clinical Sciences and Medical Services
Dr. Su Yang	Senior Vice President Of Clinical Research and PMO
Ka Man Ng A.C.I.S., A.C.S.	Company Secretary